drugset
Drugs / Fisogatinib
last change Feb 2024 re-read 9 days ago

Fisogatinib

also known as BLU-111362 · BLU-554 · X-439161

Small molecule

Developed for
hepatocellular carcinoma
Investigated by
Blueprint Medicines Corporation · CStone Pharmaceuticals

Trials 2

today NCT04194801 · Ph 1/2 NCT02508467 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02508467 Jul 2015 → Jun 2021 hepatocellular carcinoma Blueprint Medicines Corporation Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04194801 Dec 2019 → Oct 2021 hepatocellular carcinoma CStone Pharmaceuticals Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-09-18 Abbisko Therapeutics Co, Ltd Results Abbisko Therapeutics published breakthrough translational research results of FGFR4 inhibitors on an AACR journal “Molecule Cancer Therapeutics” abbisko.com ↗
The recently online article comprehensively elucidated major resistance mechanisms of the FGFR4 inhibitors, and for the first time discovered that EGFR activation is a primary factor leading to resistance to FGFR4 inhibitors in HCC.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Fisogatinib ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508467 ↗
1

NCT04194801 ↗
Known as BLU-111362 ChEMBL registry synonym — accepted as the source's own label CHEMBL4514636 ↗
Known as BLU-554 “Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W).” NCT04194801 ↗
Known as X-439161 ChEMBL registry synonym — accepted as the source's own label CHEMBL4514636 ↗
Modality Small molecule — CHEMBL4514636 ↗
Route Oral “administered orally” NCT02508467 ↗